Patents Assigned to GENINUS INC.
  • Patent number: 11866765
    Abstract: The present disclosure relates to a composition for improving molecular barcoding efficiency and a use thereof, and provided are a method for preparing a DNA library, a molecular barcoding method for nucleic acid sequencing, and a composition for preparing a DNA library. According to the method and composition, by using a barcode sequence arranged to include the position of a first nucleotide in an adapter on the basis of a terminal region of the adapter ligated with a DNA fragment, molecular barcoding switching can be reduced and the accuracy of nucleic acid sequencing can be improved.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: January 9, 2024
    Assignee: GENINUS INC.
    Inventors: Dong Hyun Park, Jong Suk Chung, Seung Ho Shin, Sol Yi Kim, Hyeyeun Lim, Hyeong Been Park
  • Patent number: 11821045
    Abstract: Provided is a colorectal cancer-specific methylation biomarker for diagnosing colorectal cancer. Since a gene marker according to an embodiment exhibits a specific methylation pattern in colorectal cancer tissue, it can be usefully used as a methylation marker for diagnosing colorectal cancer, thereby increasing the cure rate of colorectal cancer by early diagnosis and treatment of colorectal cancer.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: November 21, 2023
    Assignees: GENINUS INC., SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Jinho Kim, Woong Yang Park, Yong Beom Cho, Ga Hyun Kim, Jun Gi Jeong, Dong Hyun Park
  • Publication number: 20220325349
    Abstract: Provided is a colorectal cancer-specific methylation biomarker for diagnosing colorectal cancer. Since a gene marker according to an embodiment exhibits a specific methylation pattern in colorectal cancer tissue, it can be usefully used as a methylation marker for diagnosing colorectal cancer, thereby increasing the cure rate of colorectal cancer by early diagnosis and treatment of colorectal cancer.
    Type: Application
    Filed: April 13, 2021
    Publication date: October 13, 2022
    Applicants: GENINUS INC., SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Jinho KIM, Woong Yang PARK, Yong Beom CHO, Ga Hyun KIM, Jun Gi JEONG, Dong Hyun PARK
  • Publication number: 20220316012
    Abstract: The present invention relates to a method of analyzing a corrected TMB and a method for predicting a response to immune checkpoint inhibitors in a cancer patient using the same. According to a method, a computer-readable recording medium and an analyzing apparatus, for providing information according to an aspect, since the corrected TMB of the present invention is markedly highly predictive of the response to cancer immunotherapy in the cancer patient, compared to the conventional TMB, a patient group predicted to show a therapeutic effect can be selected and an appropriate treatment can be administered, thereby alleviating pain and treatment costs from the cancer patient.
    Type: Application
    Filed: October 29, 2020
    Publication date: October 6, 2022
    Applicant: GENINUS INC.
    Inventors: Woong-Yang PARK, Se-Hoon LEE, Joon Ho SHIM